Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper

Overview of attention for article published in Hematological Oncology, June 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (74th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 11 X users

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 14 X posts from 11 X users, with an upper bound of 44,917 followers.

Understand the potential of the B-cell surface antigen CD19 as a target for R/R DLBCL treatment in this enhanced #OpenAccess Expert Opinion Paper from #HematologicalOncology: https://t.co/pEMWCEejhz https://t.co/k0wNcvIt7H

RT @ManniMD1: It is fascinating that a review article written by a medical writer of the drug company has in title, “expert opinion paper”.…

It is fascinating that a review article written by a medical writer of the drug company has in title, “expert opinion paper”. I’ve read many review articles actually written by experts that didn’t feel compelled to highlight “expert opinion” in title. h…

Understand the potential of the B-cell surface antigen CD19 as a target for R/R DLBCL treatment in this enhanced #OpenAccess expert opinion paper from Hematological Oncology. 👇 🔗: https://t.co/2cYdpAZlj6 #Lymphoma https://t.co/2URM2URCn8

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 10 additional X posts.